Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 187048, 8 pages
http://dx.doi.org/10.1155/2015/187048
Review Article

Balancing Innate Immunity and Inflammatory State via Modulation of Neutrophil Function: A Novel Strategy to Fight Sepsis

1Department of Pathophysiology, Anhui Medical University, Hefei 230032, China
2Experimental Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
3Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
4Experimental Transplantation Surgery, Department of General, Visceral and Vascular Surgery, Jena University Hospital, 07747 Jena, Germany

Received 9 August 2015; Revised 16 November 2015; Accepted 2 December 2015

Academic Editor: Carlos Rosales

Copyright © 2015 Haoshu Fang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. S. Hotchkiss and I. E. Karl, “The pathophysiology and treatment of sepsis,” The New England Journal of Medicine, vol. 348, no. 2, pp. 138–150, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Cohen, J. L. Vincent, N. K. Adhikari et al., “Sepsis: a roadmap for future research,” The Lancet Infectious Diseases, vol. 15, no. 5, pp. 581–614, 2015. View at Publisher · View at Google Scholar
  3. A. C. Ma and P. Kubes, “Platelets, neutrophils, and neutrophil extracellular traps (NETs) in sepsis,” Journal of Thrombosis and Haemostasis, vol. 6, no. 3, pp. 415–420, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Brown, S. Brain, J. Pearson, J. Edgeworth, S. Lewis, and D. Treacher, “Neutrophils in development of multiple organ failure in sepsis,” The Lancet, vol. 368, no. 9530, pp. 157–169, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Singer, K. Y. Stokes, and D. Neil Granger, “Reactive oxygen and nitrogen species in sepsis-induced hepatic microvascular dysfunction,” Inflammation Research, vol. 62, no. 2, pp. 155–164, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Cauwels and P. Brouckaert, “Nitrite regulation of shock,” Cardiovascular Research, vol. 89, no. 3, pp. 553–559, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Aritomi, N. Kunishima, T. Okamoto, R. Kuroki, Y. Ota, and K. Morikawa, “Atomic structure of the GCSF-receptor complex showing a new cytokine-receptor recognition scheme,” Nature, vol. 401, no. 6754, pp. 713–717, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Ishikawa, H. Tanaka, Y. Nakamori et al., “Difference in the responses after administration of granulocyte colony-stimulating factor in septic patients with relative neutropenia,” Journal of Trauma-Injury Infection & Critical Care, vol. 48, no. 5, pp. 814–825, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. G. S. Chatta, T. H. Price, R. C. Allen, and D. C. Dale, “Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers,” Blood, vol. 84, no. 9, pp. 2923–2929, 1994. View at Google Scholar · View at Scopus
  10. V. Garg, H. Garg, A. Khan et al., “Granulocyte colony-stimulating factor mobilizes CD34+ cells and improves survival of patients with acute-on-chronic liver failure,” Gastroenterology, vol. 142, no. 3, pp. 505–512.e1, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. N. J. Taylor, A. Nishtala, G. K. Manakkat Vijay et al., “Circulating neutrophil dysfunction in acute liver failure,” Hepatology, vol. 57, no. 3, pp. 1142–1152, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. M. A. S. Moore, “The clinical use of colony stimulating factors,” Annual Review of Immunology, vol. 9, no. 1, pp. 159–191, 1991. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Lundblad, J. M. Nesland, and K.-E. Giercksky, “Granulocyte colony-stimulating factor improves survival rate and reduces concentrations of bacteria, endotoxin, tumor necrosis factor, and endothelin-1 in fulminant intra-abdominal sepsis in rats,” Critical Care Medicine, vol. 24, no. 5, pp. 820–826, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Villa, C. L. Shaklee, C. Meazza, D. Agnello, P. Ghezzi, and G. Senaldi, “Granulocyte colony-stimulating factor and antibiotics in the prophylaxis of a murine model of polymicrobial peritonitis and sepsis,” Journal of Infectious Diseases, vol. 178, no. 2, pp. 471–477, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Bauhofer, A. Torossian, W. Lorenz et al., “Dependence of positive effects of granulocyte colony-stimulating factor on the antibiotic regimen: evaluation in rats with polymicrobial peritonitis,” World Journal of Surgery, vol. 28, no. 8, pp. 834–844, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Bauhofer, I. Celik, U. Plaul, H. Wulf, and A. Torossian, “Effects of G-CSF and antibiotic prophylaxis in a 2 × 2 factorial design on outcome in septic rats,” Inflammation Research, vol. 53, supplement 2, pp. S126–S129, 2004. View at Publisher · View at Google Scholar
  17. L. Luo, S. Zhang, Y. Wang et al., “Proinflammatory role of neutrophil extracellular traps in abdominal sepsis,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 307, no. 7, pp. L586–L596, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. R. K. Root and D. C. Dale, “Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients,” Journal of Infectious Diseases, vol. 179, supplement 2, pp. S342–352, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Bauhofer, U. Plaul, A. Torossian et al., “Perioperative prophylaxis with granulocyte colony-stimulating factor (G-CSF) in high-risk colorectal cancer patients for an improved recovery: a randomized, controlled trial,” Surgery, vol. 141, no. 4, pp. 501–510, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. M. V. Relling, J. M. Boyett, J. G. Blanco et al., “Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment,” Blood, vol. 101, no. 10, pp. 3862–3867, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Bo, F. Wang, J. Zhu, J. Li, and X. Deng, “Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis,” Critical Care, vol. 15, no. 1, article R58, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Nelson, S. M. Belknap, R. W. Carlson et al., “A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia,” Journal of Infectious Diseases, vol. 178, no. 4, pp. 1075–1080, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. R. K. Root, R. F. Lodato, W. Patrick et al., “Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis,” Critical Care Medicine, vol. 31, no. 2, pp. 367–373, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Hartmann, J. Lammertink, G. Mansmann et al., “A randomized, placebo-controlled study of the use of filgrastim in non neutropenic patients with nosocomial pneumonia,” European Journal of Medical Research, vol. 10, no. 1, pp. 29–35, 2005. View at Google Scholar · View at Scopus
  25. A. C. Cheng, D. Limmathurotsakul, W. Chierakul et al., “A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand,” Clinical Infectious Diseases, vol. 45, no. 3, pp. 308–314, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. D. P. Stephens, J. H. Thomas, A. Higgins et al., “Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock,” Critical Care Medicine, vol. 36, no. 2, pp. 448–454, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Fang, A. Liu, J. Sun, A. Kitz, O. Dirsch, and U. Dahmen, “Granulocyte colony stimulating factor induces lipopolysaccharide (LPS) sensitization via upregulation of LPS binding protein in rat,” PLoS ONE, vol. 8, no. 2, Article ID e56654, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Hagel and F. Brunkhorst, “Sepsis,” Intensivmedizin und Notfallmedizin, vol. 48, no. 1, pp. 57–73, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. R. P. Dellinger, M. M. Levy, A. Rhodes et al., “Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012,” Intensive Care Medicine, vol. 39, no. 2, pp. 165–228, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Fleischmann, A. Scherag, N. K. Adhikari et al., “Assessment of global incidence and mortality of hospital-treated sepsis—current estimates and limitations,” American Journal of Respiratory and Critical Care Medicine, 2015. View at Publisher · View at Google Scholar
  31. R. G. Holzheimer, “Antibiotic induced endotoxin release and clinical sepsis: a review,” Journal of Chemotherapy, vol. 13, supplement 2, pp. 159–172, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Buttenschoen, P. Radermacher, and H. Bracht, “Endotoxin elimination in sepsis: physiology and therapeutic application,” Langenbeck's Archives of Surgery, vol. 395, no. 6, pp. 597–605, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Hayashi, “Polymyxin B hemoperfusion (PMX-F) for severe sepsis and septic shock,” Nihon Rinsho, vol. 70, no. 2, pp. 311–314, 2012. View at Google Scholar · View at Scopus
  34. H. Huang, Y.-J. Wang, A. P. White et al., “Salmonella expressing a T-cell epitope from Sendai virus are able to induce anti-infection immunity,” Journal of Medical Microbiology, vol. 58, no. 9, pp. 1236–1242, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. M. J. Araña, M. G. Vallespi, G. Chinea et al., “Inhibition of LPS-responses by synthetic peptides derived from LBP associates with the ability of the peptides to block LBP-LPS interaction,” Journal of Endotoxin Research, vol. 9, no. 5, pp. 281–291, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. E. A. Panacek, J. C. Marshall, T. E. Albertson et al., “Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′) 2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels,” Critical Care Medicine, vol. 32, no. 11, pp. 2173–2182, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Roger, C. Froidevaux, D. Le Roy et al., “Protection from lethal Gram-negative bacterial sepsis by targeting Toll-like receptor 4,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 7, pp. 2348–2352, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. X. Wittebole, D. Castanares-Zapatero, and P. F. Laterre, “Toll-like receptor 4 modulation as a strategy to treat sepsis,” Mediators of Inflammation, vol. 2010, Article ID 568396, 9 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Tidswell and S. P. LaRosa, “Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis,” Expert Review of Anti-Infective Therapy, vol. 9, no. 5, pp. 507–520, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Barochia, S. Solomon, X. Cui, C. Natanson, and P. Q. Eichacker, “Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies,” Expert Opinion on Drug Metabolism and Toxicology, vol. 7, no. 4, pp. 479–494, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. W. J. Christ, O. Asano, A. L. C. Robidoux et al., “E5531, a pure endotoxin antagonist of high potency,” Science, vol. 268, no. 5207, pp. 80–83, 1995. View at Publisher · View at Google Scholar · View at Scopus
  42. P. S. Tobias, K. Soldau, and R. J. Ulevitch, “Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein,” The Journal of Biological Chemistry, vol. 264, no. 18, pp. 10867–10871, 1989. View at Google Scholar · View at Scopus
  43. S. M. Opal, J. E. Palardy, M. N. Marra, C. J. Fisher Jr., B. M. McKelligon, and R. W. Scott, “Relative concentrations of endotoxin-binding proteins in body fluids during infection,” The Lancet, vol. 344, no. 8920, pp. 429–431, 1994. View at Publisher · View at Google Scholar · View at Scopus
  44. T. R. Martin, J. C. Mathison, P. S. Tobias et al., “Lipopolysaccharide binding protein enhances the responsiveness of alveolar macrophages to bacterial lipopolysaccharide. Implications for cytokine production in normal and injured lungs,” The Journal of Clinical Investigation, vol. 90, no. 6, pp. 2209–2219, 1992. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Fierer, M. A. Swancutt, D. Heumann, and D. Golenbock, “The role of lipopolysaccharide binding protein in resistance to Salmonella infections in mice,” The Journal of Immunology, vol. 168, no. 12, pp. 6396–6403, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. R. M. Minter, X. Bi, G. Ben-Josef et al., “LPS-binding protein mediates LPS-induced liver injury and mortality in the setting of biliary obstruction,” The American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 296, no. 1, pp. G45–G54, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. R. S. Jack, X. Fan, M. Bernheiden et al., “Lipopolysaccharide-binding protein is required to combat a murine gram-negative bacterial infection,” Nature, vol. 389, no. 6652, pp. 742–745, 1997. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Hellman and H. S. Warren, “Antiendotoxin strategies,” Infectious Disease Clinics of North America, vol. 13, no. 2, pp. 371–386, 1999. View at Publisher · View at Google Scholar · View at Scopus
  49. F. Pène, E. Courtine, F. Ouaaz et al., “Toll-like receptors 2 and 4 contribute to sepsis-induced depletion of spleen dendritic cells,” Infection and Immunity, vol. 77, no. 12, pp. 5651–5658, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Knapp, A. F. de Vos, S. Florquin, D. T. Golenbock, and T. van Der Poll, “Lipopolysaccharide binding protein is an essential component of the innate immune response to Escherichia coli peritonitis in mice,” Infection and Immunity, vol. 71, no. 12, pp. 6747–6753, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Le Roy, F. Di Padova, R. Tees et al., “Monoclonal antibodies to murine lipopolysaccharide (LPS)-binding protein (LBP) protect mice from lethal endotoxemia by blocking either the binding of LPS to LBP or the presentation of LPS/LBP complexes to CD14,” The Journal of Immunology, vol. 162, no. 12, pp. 7454–7460, 1999. View at Google Scholar · View at Scopus
  52. Y. Liu, B. Ni, J.-D. Ren et al., “Cyclic limulus anti-lipopolysaccharide (LPS) factor-derived peptide CLP-19 antagonizes LPS function by blocking binding to LPS binding protein,” Biological and Pharmaceutical Bulletin, vol. 34, no. 11, pp. 1678–1683, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Liu, S. Weiss, H. Fang et al., “Lipopolysaccharide-binding protein (LBP) blockade augments the protective effect of granulocyte colony-stimulating factor (G-CSF) in a rat sepsis model,” Shock, vol. 43, no. 5, pp. 497–503, 2015. View at Publisher · View at Google Scholar
  54. K. K. Yang, B. G. Dorner, U. Merkel et al., “Neutrophil influx in response to a peritoneal infection with Salmonella is delayed in lipopolysaccharide-binding protein or CD14-deficient mice,” Journal of Immunology, vol. 169, no. 8, pp. 4475–4480, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Hartung, S. Von Aulock, C. Schneider, and E. Faist, “How to leverage an endogenous immune defense mechanism: the example of granulocyte colony-stimulating factor,” Critical Care Medicine, vol. 31, no. 1, supplement, pp. S65–S75, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. H. Tanaka, M. Nishino, Y. Nakamori et al., “Granulocyte colony-stimulating factor (G-CSF) stiffens leukocytes but attenuates inflammatory response without lung injury in septic patients,” Journal of Trauma-Injury Infection & Critical Care, vol. 51, no. 6, pp. 1110–1116, 2001. View at Publisher · View at Google Scholar · View at Scopus